Apimeds Pharmaceuticals Us (APUS)
Market Price (3/30/2026): $1.89 | Market Cap: $2.4 MilSector: Health Care | Industry: Pharmaceuticals
Apimeds Pharmaceuticals Us (APUS)
Market Price (3/30/2026): $1.89Market Cap: $2.4 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -270% | Weak multi-year price returns2Y Excs Rtn is -113%, 3Y Excs Rtn is -153% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.1 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -219% | ||
| High stock price volatilityVol 12M is 157% | ||
| Key risksAPUS key risks include [1] its dependence on a second Phase 3 trial for its sole drug candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -270% |
| Weak multi-year price returns2Y Excs Rtn is -113%, 3Y Excs Rtn is -153% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.1 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -219% |
| High stock price volatilityVol 12M is 157% |
| Key risksAPUS key risks include [1] its dependence on a second Phase 3 trial for its sole drug candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Apimeds Pharmaceuticals Us (APUS) stock has lost about 95% since 11/30/2025 because of the following key factors:
1. Strategic Merger and Substantial Financing Infusion: Apimeds Pharmaceuticals US (APUS) merged with MindWave Innovations, integrating its biotech focus with MindWave's AI-driven digital treasury yield generation strategy on December 1, 2025. This merger was immediately followed by the closing of a $100 million Private Investment in Public Equity (PIPE) financing on December 10, 2025, which included the activation of 1,000 Bitcoin to power the AI-driven yield generation strategy. This significant capital injection and strategic pivot into AI and digital assets provided a strong positive catalyst for the stock.
2. Advancing Lead Clinical Asset with FDA Engagement: The company announced on February 11, 2026, that an FDA Type C meeting was scheduled with Lōkahi Therapeutics for its lead product candidate, LT-100 (Apitox). Apitox is a bee venom-based toxin in late-stage clinical development for osteoarthritis pain, and this meeting signifies crucial regulatory progress and ongoing engagement with the FDA towards potential approval.
Show more
1. Strategic Merger and Substantial Financing Infusion: Apimeds Pharmaceuticals US (APUS) merged with MindWave Innovations, integrating its biotech focus with MindWave's AI-driven digital treasury yield generation strategy on December 1, 2025. This merger was immediately followed by the closing of a $100 million Private Investment in Public Equity (PIPE) financing on December 10, 2025, which included the activation of 1,000 Bitcoin to power the AI-driven yield generation strategy. This significant capital injection and strategic pivot into AI and digital assets provided a strong positive catalyst for the stock.
2. Advancing Lead Clinical Asset with FDA Engagement: The company announced on February 11, 2026, that an FDA Type C meeting was scheduled with Lōkahi Therapeutics for its lead product candidate, LT-100 (Apitox). Apitox is a bee venom-based toxin in late-stage clinical development for osteoarthritis pain, and this meeting signifies crucial regulatory progress and ongoing engagement with the FDA towards potential approval.
Show more
Stock Movement Drivers
Fundamental Drivers
The -93.4% change in APUS stock from 11/30/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.00 | 1.91 | -93.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| APUS | -93.4% | |
| Market (SPY) | -5.3% | 14.1% |
| Sector (XLV) | -8.7% | -1.4% |
Fundamental Drivers
The -89.6% change in APUS stock from 8/31/2025 to 3/29/2026 was primarily driven by a -17.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.30 | 1.91 | -89.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | -17.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| APUS | -89.6% | |
| Market (SPY) | 0.6% | 16.1% |
| Sector (XLV) | 5.2% | -1.8% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| APUS | ||
| Market (SPY) | 9.8% | 10.7% |
| Sector (XLV) | -2.1% | -0.8% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| APUS | ||
| Market (SPY) | 69.4% | 10.7% |
| Sector (XLV) | 18.4% | -0.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| APUS Return | - | - | - | - | -25% | -90% | -93% |
| Peers Return | 29% | 3% | 2% | -5% | 31% | 2% | 73% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| APUS Win Rate | - | - | - | - | 50% | 33% | |
| Peers Win Rate | 55% | 53% | 45% | 43% | 57% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| APUS Max Drawdown | - | - | - | - | -31% | -90% | |
| Peers Max Drawdown | -9% | -17% | -25% | -18% | -8% | -9% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PCRX, PFE, JNJ, LLY, AMGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
APUS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to PCRX, PFE, JNJ, LLY, AMGN
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Apimeds Pharmaceuticals Us (APUS)
We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apitox is currently marketed and sold by Apimeds Inc. (“Apimeds Korea”) in the South Korea as “Apitoxin.” Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not been approved by the U.S. Food and Drug Administration (the “FDA”) for any indication. Apimeds is currently developing Apitox as a potential osteoarthritis (“OA”) treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. In 2003, after completing successful Phase I, II, and III trials, the Korean Ministry of Food and Drug Safety (the “MFDA”) approved the use of Apitoxin to treat pain and mobility in patients with OA in South Korea. Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003. Additionally, a post-marketing/approval safety study in South Korea followed 3,194 patients from 2003 through 2009, with no serious adverse events. In 2013, the FDA authorized Apimeds Korea to conduct a preliminary Phase III to study the same indication approved in South Korea — the use of Apitoxin to treat pain and inflammation in patients with OA — which was completed in 2018 (the “Apimeds Korea Phase III OA Trial”). On August 2, 2021, we entered into an agreement with Apimeds Korea, a principal stockholder of Apimeds US (the “Business Agreement”). Pursuant to the Business Agreement, Apimeds Korea granted to the Company a sublicensable, royalty-bearing license to utilize all prior clinical development data associated with Apitoxin, Apitox, and all related names, and to advance clinical research, develop, manufacture and commercialize and sell Apitox in the United States. Based on the results from the Apimeds Korea Phase III OA Trial, which demonstrated therapeutic effect in the treatment group compared to the placebo group, but in combination with prior development by Apimeds Korea, did not meet the FDA’s standards for approval, as the study population was too small and the methods for handling missing data were inadequate, resulting in a study that did not demonstrate a significant treatment effect. We will be pursuing a second Phase III trial to meet agreed upon FDA standards. Based on results from the Apimeds Korea Phase III OA Trial, we have evaluated the most appropriate population, defined as advanced knee OA patients, which will range from defined grade 2, 3 and 4 within this treatment group, to continue to progress our own Phase III trial in knee OA. Pursuant to our previous correspondence with the FDA, we have designed and will implement our Phase III trial to best address our patient population, appropriate dosing, and the most effective way to evaluate Apitox in meeting the patient population’s needs. Apimeds Korea has also engaged in clinical trials to explore the therapeutic effect of Apitoxin in patients with multiple sclerosis (“MS”), including in 2014, submitting an Investigational New Drug Application (“IND”) 122804 to run a Phase III clinical trial. Pursuant to the Business Agreement, Apimeds Korea transferred sponsorship of IND 122804 to Apimeds US in October 2020. Pursuant to the written correspondence from the FDA, as of the date of this prospectus, there are no clinical holds relating to the planned clinical trials. However, we have made the strategic decision to focus our MS efforts on the early prosecution of appropriate patient populations through non-registered corporate sponsorship studies and will not be pursuing a Phase III trial for MS at this time. Chronic diseases such as OA and MS cause considerable economic, personal, and societal burden. These diseases negatively impact quality of life and progress from the time of onset until death. We are dedicated to developing innovative therapies using Apitox that seek to restore the health and enhance the quality of life of patients suffering with these diseases. To this date, Apimeds has generated no revenue from the sale and or distribution of Apitox in the United States. We have generated our clinical data and an opportunity to advance treatment opportunities with proceeds received from sales of our securities to prior investors and the work of our partners, Apimeds Korea and Inscobee Inc. We do not currently hold any debt as prior investments in the form of convertible notes have since been converted to equity. We believe that naturalized bee venom can provide an additive treatment, that pending clinical demonstration of success and FDA approval, could provide value to OA patients in need and the physicians treating OA patients, and potentially MS. The advancement of Apitox as a candidate and Apimeds as a company, will be dictated by the clinical data and the regulatory agencies interpretation of such data in regard to effectiveness, safety and potential benefit beyond existing treatment options. Apimeds US was incorporated in Delaware on May 11, 2020. We are located at 2 East Broad Street, 2nd Floor, Hopewell, New Jersey.
AI Analysis | Feedback
Apimeds Pharmaceuticals Us (APUS) is like:
- A **smaller, specialized version of GW Pharmaceuticals** (known for developing cannabis-based drugs), but focused on bringing **bee venom-based therapies** that are already approved and sold in South Korea through the rigorous **US FDA approval process**.
AI Analysis | Feedback
Major Products
- Apitox for Osteoarthritis (OA): An intradermally administered bee venom-based toxin currently in Phase III clinical development as a potential treatment for knee pain associated with osteoarthritis.
AI Analysis | Feedback
```htmlApimeds Pharmaceuticals Us (APUS) is a clinical-stage biopharmaceutical company focused on developing Apitox. Based on the provided description, the company has not yet generated any revenue from the sale or distribution of Apitox in the United States.
Therefore, Apimeds Pharmaceuticals Us does not currently have any major customers, either other companies or individuals, for its product.
```AI Analysis | Feedback
- Apimeds Inc.
- Inscobee Inc.
AI Analysis | Feedback
Dr. Vin Menon, Chief Executive Officer and Director
Dr. Vin Menon is a veteran in the technology services industry, credited with the strategic direction behind several disruptive technology companies. He has held various leadership positions at multinational corporations like HP & Compaq with global responsibilities. Driven by his passion for technology and innovation, Dr. Menon has been a forerunner in technological innovation and has helped create the business ecosystem of disruptive technologies and high-growth companies. His experience has helped him as an entrepreneur and advisor, leading several startups from inception to meteoric growth across continents. Dr. Menon's proven track record of setting up motivated and high-caliber teams, establishing development centers from scratch to scale, and building company competencies led him to being awarded 'Entrepreneur of the Year 2012' by Rotary-ASME, 'Outstanding Entrepreneur Award 2011' by APEA, and the 'Spirit of Enterprise 2010' by SOE Singapore. He was also selected as a 'Leading Indian Entrepreneur of the Year 2010' by the Singapore Indian Chamber of Commerce. From 2021 to 2023, he co-founded and served as Strategic Advisor to CGCX, a Fintech, decentralized finance, and digital assets platform, where he provided strategic advisory services and growth initiatives. He currently serves as Chief Executive Officer of AQUAE Impact, a sustainable financial and environmental assets platform that uses blockchain technology and artificial intelligence, which he co-founded and currently forms part of its executive leadership providing oversight of product and sustainability initiatives. He also currently serves as Chief Executive Officer of AQUAE Labs Pte Ltd, the research and development and technology arm of AQUAE Impact, where he provides product and technology leadership.
Erick J. Frim, Chief Financial Officer
Mr. Frim has over 40 years of experience as an accountant, financial executive, and consultant. He joined Helio Corporation in December 2024. In 2019, he joined CFO Squad as a partner, where he advised clients on technical accounting and regulatory compliance, assisting numerous companies with their initial public offerings. Prior to CFO Squad, Mr. Frim served as a director in the public company audit practice of EisnerAmper LLP. He also served as a financial executive for digital media pioneer DIVA Systems Corporation. Mr. Frim is a former CPA.
Erik Emerson, President & Director
Mr. Emerson's annual base salary was increased to $500,000 effective November 13, 2025. The amendment to his executive employment agreement also updated severance terms.
Dr. Christopher Kim, MD, Chief Medical Officer
Dr. Christopher Kim served as the interim Chief Executive Officer of Apimeds Pharmaceuticals US from July 2022 to September 2023.
Susan Kramer, DrPH, Senior Vice President, Development
Dr. Kramer possesses more than 30 years of experience in biopharmaceutical research and development, with her first 18 years spent at Genentech. She was a co-founder of Corthera, Inc., which was later acquired by Novartis. Dr. Kramer has also held senior management and key alliance management roles at various other biotech companies, including XOMA, Anesiva, and Annexon Biosciences. Most recently, she served as Executive Vice President of Development at Concentric Analgesics.
AI Analysis | Feedback
Key Business Risks for Apimeds Pharmaceuticals US (APUS)
- Failure to obtain U.S. Food and Drug Administration (FDA) approval for Apitox. The company's entire business model is contingent upon the successful completion of a second Phase III clinical trial and subsequent FDA approval for Apitox as an osteoarthritis treatment. A previous Phase III trial by Apimeds Korea did not meet FDA standards due to an insufficient study population and inadequate data handling, highlighting significant regulatory hurdles.
- Lack of commercialized products and revenue. Apimeds US currently generates no revenue from the sale or distribution of Apitox in the United States and is dependent on proceeds from security sales to prior investors for its operations.
- Competition from existing osteoarthritis treatments. The successful market entry of Apitox is dependent on demonstrating clinical benefits beyond current treatment options for osteoarthritis, which could pose a challenge in a competitive therapeutic landscape.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable market for Apimeds Pharmaceuticals US (APUS)'s main product, Apitox, as a potential treatment for knee osteoarthritis, is the U.S. knee osteoarthritis treatment market. This market was valued at approximately USD 8.9 billion in 2023. Projections indicate that the knee osteoarthritis market in the U.S. is expected to grow, with some estimates suggesting it will reach US$ 9.1 billion by 2034.AI Analysis | Feedback
Apimeds Pharmaceuticals US (APUS) is a clinical-stage biopharmaceutical company primarily focused on developing Apitox, a bee venom-based toxin, for the treatment of knee osteoarthritis. As the company currently generates no revenue from product sales in the United States, its future revenue growth over the next 2-3 years is anticipated to be driven by the following key factors:- Successful Completion of Phase III Clinical Trial and U.S. FDA Approval for Apitox in Knee Osteoarthritis: The primary driver of future revenue will be the successful completion of its second Phase III clinical trial for Apitox as a treatment for advanced knee osteoarthritis, followed by obtaining U.S. Food and Drug Administration (FDA) marketing approval. This regulatory milestone is a prerequisite for commercialization and revenue generation from product sales in the U.S.
- Commercial Launch and Market Penetration of Apitox for Advanced Knee Osteoarthritis: Following FDA approval, revenue growth will be driven by the successful commercial launch of Apitox in the U.S. market. This includes the effective marketing, sales, and increasing adoption of Apitox by healthcare providers and patients suffering from advanced knee osteoarthritis, leading to growing sales volumes.
- Revenue Generation from MindWave Innovations' Digital Treasury and Digital Asset Yield Generation: A significant new driver of company revenue is the merger with MindWave Innovations Inc. in December 2025. This integration introduces an AI-driven digital treasury and digital asset yield generation business, which aims to provide substantial cash flow and accelerate Apimeds' therapeutic programs. This represents a distinct, non-biopharmaceutical revenue stream contributing to overall company growth.
- Expansion of Apitox's Indications to Other Inflammatory and Autoimmune Diseases: Beyond knee osteoarthritis, Apimeds Pharmaceuticals US has indicated plans to explore and potentially advance Apitox for other inflammatory and autoimmune conditions, such as rheumatoid arthritis, lupus, and psoriasis. While commercial sales from these new indications may extend beyond the immediate 2-3 year timeframe, progress in preclinical or clinical stages for these additional indications would significantly drive future revenue growth potential and enhance the company's valuation.
AI Analysis | Feedback
Share Issuance
- The company issued securities to prior investors, generating proceeds to fund clinical data development and advance treatment opportunities.
- Prior investments in the form of convertible notes were converted into equity.
Inbound Investments
- The company received proceeds from the sale of its securities to prior investors.
- Convertible notes from prior investments were converted into equity, which eliminated existing debt.
- On August 2, 2021, Apimeds Korea, a principal stockholder, granted Apimeds US a sublicensable, royalty-bearing license to utilize all prior clinical development data for Apitox and to advance clinical research, develop, manufacture, and commercialize Apitox in the United States.
Trade Ideas
Select ideas related to APUS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 133.75 |
| Mkt Cap | 170.7 |
| Rev LTM | 49,665 |
| Op Inc LTM | 13,243 |
| FCF LTM | 7,032 |
| FCF 3Y Avg | 4,488 |
| CFO LTM | 10,831 |
| CFO 3Y Avg | 9,965 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.0% |
| Rev Chg 3Y Avg | 2.9% |
| Rev Chg Q | 8.6% |
| QoQ Delta Rev Chg LTM | 2.2% |
| Op Mgn LTM | 27.2% |
| Op Mgn 3Y Avg | 24.8% |
| QoQ Delta Op Mgn LTM | 0.9% |
| CFO/Rev LTM | 25.8% |
| CFO/Rev 3Y Avg | 23.6% |
| FCF/Rev LTM | 18.8% |
| FCF/Rev 3Y Avg | 20.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 170.7 |
| P/S | 5.1 |
| P/EBIT | 16.6 |
| P/E | 23.0 |
| P/CFO | 16.0 |
| Total Yield | 5.0% |
| Dividend Yield | 1.4% |
| FCF Yield 3Y Avg | 5.3% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.7% |
| 3M Rtn | -4.1% |
| 6M Rtn | 19.7% |
| 12M Rtn | 11.3% |
| 3Y Rtn | 19.5% |
| 1M Excs Rtn | 3.2% |
| 3M Excs Rtn | 4.7% |
| 6M Excs Rtn | 24.5% |
| 12M Excs Rtn | -0.5% |
| 3Y Excs Rtn | -37.9% |
Price Behavior
Price Behavior
| Market Price | $1.91 | |
| Market Cap ($ Bil) | 0.0 | |
| Distance from 52W High | -95.1% | |
| 50 Days | 200 Days | |
| DMA Price | $11.96 | $11.95 |
| DMA Trend | down | down |
| Distance from DMA | -84.0% | -84.0% |
| 3M | 1YR | |
| Volatility | 228.8% | 156.8% |
| Downside Capture | 7.40 | 3.66 |
| Upside Capture | 297.30 | 184.60 |
| Correlation (SPY) | 17.1% |
APUS Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 6.93 | 5.41 | 4.49 | 3.03 | -0.13 | -0.54 |
| Up Beta | 4.47 | 2.25 | 2.23 | 0.81 | -0.40 | 0.56 |
| Down Beta | 17.17 | 7.51 | 6.16 | 3.32 | 0.12 | -0.26 |
| Up Capture | 289% | 520% | 189% | 393% | 150% | 18% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 7 | 17 | 23 | 51 | 86 | 86 |
| Down Capture | 585% | 470% | 459% | 276% | 147% | 94% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 13 | 22 | 35 | 68 | 108 | 108 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with APUS | |
|---|---|---|---|---|
| APUS | -91.4% | 156.8% | -0.37 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | -0.8% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 10.7% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 20.9% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 8.8% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 0.6% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 13.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with APUS | |
|---|---|---|---|---|
| APUS | -38.7% | 156.8% | -0.37 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | -0.8% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 10.7% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 20.9% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 8.8% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 0.6% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 13.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with APUS | |
|---|---|---|---|---|
| APUS | -21.7% | 156.8% | -0.37 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | -0.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 10.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 20.9% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 8.8% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 0.6% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 13.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kim, Christopher | Chairman and CMO | Direct | Buy | 5152025 | 1.82 | 19,770 | 35,981 | 35,981 | Form |
| 2 | Kim, Christopher | Chairman and CMO | Direct | Buy | 5152025 | 1.86 | 7,730 | 14,378 | 51,150 | Form |
| 3 | Koo, Jakap | Direct | Buy | 5142025 | 1.99 | 28,500 | 56,715 | 1,281,331 | Form | |
| 4 | Inscobee, Inc. | Direct | Buy | 5142025 | 4.00 | 500,000 | 2,000,000 | 7,938,464 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.